Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 12 de 12
1.
Eur J Cancer ; 38 Suppl 4: S24-30, 2002 Mar.
Article En | MEDLINE | ID: mdl-11858960

New anticancer treatments (new therapeutic strategies or new compounds) require careful development in which cancer clinical trials are an essential element. Two scientific committees, namely the New Treatment Committee and the Protocol Review Committee, ensure the review of all EORTC protocols with respect to the interest and originality, methodology, feasibility and relevance within the EORTC framework. Both Committees are involved early in the evaluation of the new concept proposal and follow all aspects (methodology, administrative, regulatory) of the protocol development process. Throughout its 25 years of existence, the Protocol Review Committee has streamlined drug and protocol evaluations and has developed standard operating procedures to handle those reviews in a very efficient and fast manner. Since 1997, the New Treatment Committee has contributed to strengthening the EORTC during the development process with the aim of ensuring an optimal flow of information on new drugs between laboratory and clinical research divisions.


Clinical Protocols/standards , Clinical Trials as Topic/standards , International Agencies/organization & administration , Medical Oncology/organization & administration , Neoplasms/therapy , Professional Staff Committees/organization & administration , Europe , Humans , Research/standards
2.
Toxicol Lett ; 110(1-2): 29-33, 1999 Oct 29.
Article En | MEDLINE | ID: mdl-10593592

Although the morphological description of sulfur mustard (SM) injury is well characterised, little is known of the molecular mediators involved in cutaneous toxicity. Since infiltration by lymphocytes and PMNs represents one of the very first events observed in vivo upon exposure to SM, this study examined whether SM exposure can modify the expression by cultured human keratinocytes of interleukin-8, one of the most important chemoattractants for polymorphonuclear leukocytes (PMNs) in humans. Conditioned medium harvested from control keratinocyte cultures showed a gradual accumulation of this cytokine over time followed by a levelling off after 12 hours. Upon treatment with 10(-6) and 10(-5) M SM, no significant difference compared to the control situation was observed. After 6 h, a significantly higher amount of IL-8 was secreted by human keratinocytes treated with 10(-4) M SM and the accumulation of the cytokine persisted up to 24 h after exposure. The expression of IL-8 mRNA was assessed semi-quantitatively (RT-PCR) at the same time points in control and SM-treated (10(-4) M) human keratinocytes. When compared to control cultures, a clear upregulation of IL-8 mRNA levels was observed 6 and 12 h after SM exposure, which is consistent with the secretion pattern of the protein. The present observation indicates that increased secretion of IL-8 by human keratinocytes represents an early event of the inflammatory reaction following SM which is coherent with the reported delay in the recruitment of lymphocytes and PMNs observed in vivo.


Chemical Warfare Agents/toxicity , Interleukin-8/biosynthesis , Keratinocytes/drug effects , Mustard Gas/pharmacology , Up-Regulation , Animals , Cells, Cultured , Chemotactic Factors/biosynthesis , Humans , Indicators and Reagents , Interleukin-1/biosynthesis , Keratinocytes/metabolism , RNA, Messenger/biosynthesis , Rabbits , Reverse Transcriptase Polymerase Chain Reaction , Tumor Necrosis Factor-alpha/biosynthesis
3.
Am J Respir Cell Mol Biol ; 20(4): 561-72, 1999 Apr.
Article En | MEDLINE | ID: mdl-10100987

Interleukin (IL)-12 is a cytokine produced principally by activated macrophages which is involved in control of the T-helper 1/T-helper 2 cell (Th1/Th2) polarization of immune responses. To examine its potential involvement in the development of lung fibrosis, we examined the expression (protein, messenger RNA [mRNA]) of IL-12 (p70) and of its subunits (p40 and p35) in lung homogenates, bronchoalveolar lavage fluid (BALF), and bronchoalveolar lavage (BAL) cell cultures in mouse models of resolutive alveolitis (RA) and fibrosing alveolitis (FA) induced by inorganic particles (manganese dioxide [MnO2] and crystalline silica, respectively). The administration of tungsten carbide (WC), which behaved as an innocuous dust for the lung, served as a negative control condition. The FA was specifically accompanied by a Th2-like polarization characterized by high levels of immunoglobulin (Ig)G1 in BALF and by a protracted overproduction of both p40 protein and mRNA, but not by the biologically active form of IL-12 (p70). In the RA model, the p40 response was only transient, and a Th1-like response was reflected by increased levels of interferon (IFN)-gamma and dominant levels of IgG2a in BALF. Taken together, these findings suggest that production of the p40 subunit of IL-12 and Th2 polarization play important roles in lung inflammatory and fibrotic responses to inhaled inorganic particles.


Interleukin-12/genetics , Lung/immunology , Pulmonary Fibrosis/immunology , Silicon Dioxide , Th2 Cells/immunology , Animals , Antibody Formation , Bronchoalveolar Lavage Fluid/immunology , Cells, Cultured , Female , Gene Expression Regulation/immunology , Immunoglobulin G/biosynthesis , Immunoglobulin G/genetics , Lung/pathology , Macromolecular Substances , Manganese Compounds , Mice , Mice, Inbred Strains , Oxides , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/pathology , RNA, Messenger/genetics , Transcription, Genetic , Tungsten Compounds
4.
J Toxicol Environ Health A ; 55(5): 359-71, 1998 Nov 13.
Article En | MEDLINE | ID: mdl-9829559

Since tumor growth factor beta (TGF-beta) and its receptor are ubiquitously expressed and because latent TGF-beta cannot bind to the cell surface receptor, the ability of a cell to activate latent TGF-beta upon secretion represents an important regulatory mechanism of TGF-beta action. In vivo, the protease plasmin is considered to be one of the main enzymes operative in the proteolytic cleavage of the latency-associated peptide moiety from TGF-beta, which converts it into the biologically active form. The TGF-beta response was characterized in alveolar macrophages during pulmonary inflammation (d 3) and fibrosis (d 120) induced by a single intratracheal instillation of silica particles (5 mg/mouse). To appreciate the role of urokinase-type plasminogen activator (uPA) in the activation of TGF-beta, the production of total, active and latent TGF-beta by explanted alveolar macrophages was compared in uPA-deficient (uPA-/-) mice and their normal counterparts (uPA+/+). At d 3 and 120 after silica treatment, a significant increase in cell-associated PA activity was found in uPA+/+ mice compared to that of saline controls. As expected, this response was almost totally absent in uPA-/- mice. Alveolar macrophages from uPA+/+ controls were found to release TGF-beta mainly expressed in a biologically active form. In response to silica treatment, inflammatory cells were found to upregulate, especially at the fibrotic stage, their secretion of total and bioactive TGF-beta. No significant difference was found between uPA-/- and uPA+/+ silica-treated animals for the expression of total, active, or latent TGF-beta. Although it has previously been reported that macrophage surface activation of TGF-beta is dependent on both plasmin generation and uPA cell surface receptor, no evidence was found to support this hypothesis in the present study.


Macrophages, Alveolar/metabolism , Pulmonary Fibrosis/metabolism , Transforming Growth Factor beta/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Animals , Biomarkers/analysis , Cells, Cultured , Female , Macrophages, Alveolar/drug effects , Macrophages, Alveolar/enzymology , Male , Mice , Mice, Knockout , Pulmonary Fibrosis/chemically induced , Silicon Dioxide , Tissue Plasminogen Activator/analysis , Transforming Growth Factor beta/analysis , Urokinase-Type Plasminogen Activator/deficiency , Urokinase-Type Plasminogen Activator/pharmacology
5.
Eur Respir J ; 11(4): 912-21, 1998 Apr.
Article En | MEDLINE | ID: mdl-9623697

Altered expression of plasminogen activator inhibitors (PAIs) is of potential relevance to the process of lung fibrosis. To clarify the involvement of PAIs in interstitial lung diseases, we examined whether alterations in PAI-1 and PAI-2 were induced in response to a single intratracheal administration of a fibrosing dose of crystalline silica in mice (5 mg x animal(-1)). The time course of changes in PAI activity and PAI-1 protein were characterized in bronchoalveolar lavage fluid (BALF) and changes in PAI-1 and PAI-2 messenger ribonucleic acid (mRNAs) were monitored by reverse transcriptase polymerase chain reaction (RT-PCR) in BALF cells and lung tissue up to the fibrotic stage of the disease. Substantial levels of PAI activity were found in BALF of control animals, whereas no PAI-1 protein was detected. In response to silica treatment, we observed an acute increase of PAI activity and PAI-1 protein levels in BALF (day 1), associated with an induction of PAI-1 and PAI-2 mRNA levels in lung tissue. In alveolar macrophages, silica treatment induced a persistent upregulation of PAI-2 mRNA only. One month after silica treatment, PAI activity was undetectable in BALF while substantial PAI activity was still present in controls. At the same time point, sustained upregulation of PAI-1 and PAI- 2 mRNAs was, however, noted in lung tissue of animals treated with silica. These findings support the possible implication of PAIs in the remodelling process induced by silica in the lung.


Lung/chemistry , Lung/drug effects , Plasminogen Activator Inhibitor 1/analysis , Plasminogen Activator Inhibitor 2/analysis , Silicon Dioxide/toxicity , Animals , Bronchoalveolar Lavage Fluid/chemistry , Female , Lung Diseases/chemically induced , Mice , Models, Biological , Polymerase Chain Reaction , RNA, Messenger/analysis , Up-Regulation
6.
Am J Physiol ; 274(6): L1040-8, 1998 06.
Article En | MEDLINE | ID: mdl-9609744

Impaired fibrinolytic activity and persistent fibrin deposits in lung tissue have been associated with lung fibrotic disorders. The present study examined the sources of plaminogen activator (PA) changes induced by a single intratracheal administration of silica particles (5 mg) in the mouse lung. We found in both control and silica-treated animals that amiloride almost totally abolished PA activity in bronchoalveolar lavage (BAL) fluid (BALF), indicating that initial upregulation (from day 1) as well as sustained PA activity (up to day 30) observed in response to silica is related to changes in urokinase-type PA (uPA). The upregulation of BALF uPA activity was associated with a marked and persistent increase in uPA mRNA levels in lung tissue. Changes in uPA expression were also reflected in the BAL cell fraction. A maximal and constant increase in cell uPA activity was associated with the early response to silica, whereas significant but lower upregulation was still noted at the fibrotic stage. From days 3 to 30, a progressive increase in uPA mRNA levels was noted in BAL inflammatory cells elicited by silica. Because the number of BAL neutrophils was strongly correlated with BALF and BAL cell-associated uPA activity, their involvement in uPA upregulation was addressed by inducing neutropenia with cyclophosphamide (200 mg/kg ip) before administration of the silica. Neutrophilic depletion did not, however, reduce, and even increased, the BAL cell-associated uPA activity. At the BALF level, neutropenia did not change PA activity in silica-treated mice, pointing to alveolar macrophages as the principal source of uPA in response to silica. Immunohistochemical stainings identified alveolar macrophages and pneumocytes as uPA-expressing cells in silica-treated animals (day 30). Intense and heterogenous staining was observed in silicotic nodules. These findings indicate that urokinase produced by alveolar macrophages is operative not only at the alveolitis stage but also later in the fibrotic process, produced by silica particles, supporting the role of uPA in fibrogenesis.


Gene Expression Regulation/drug effects , Lung/enzymology , Macrophages, Alveolar/enzymology , Silicon Dioxide/pharmacology , Urokinase-Type Plasminogen Activator/genetics , Amiloride/pharmacology , Animals , Bronchoalveolar Lavage Fluid , Female , Humans , Immunohistochemistry , Mice , Neutrophils/physiology , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , RNA-Directed DNA Polymerase , Urokinase-Type Plasminogen Activator/metabolism
7.
Am J Respir Crit Care Med ; 157(2): 617-28, 1998 Feb.
Article En | MEDLINE | ID: mdl-9476881

The lung plasminogen activator (PA) response was examined in four different models of particle-induced pulmonary lesions in NMRI mice (single intratracheal administration, 0.75 to 5 mg/mouse). Sequential changes in cellular (total and differential counts) and biochemical markers of alveolitis (lactate dehydrogenase [LDH], total proteins) were monitored in bronchoalveolar fluid (BALF) and the fibrotic lung response was assessed histologically. An intense but spontaneously resolving alveolitis was produced by manganese dioxide (MnO2) and a fibrosing alveolitis was elicited by crystalline silica (DQ12). Minimal and noninflammatory responses were obtained after instillation of titanium dioxide (TiO2) and tungsten carbide (WC), respectively. The comparison between the resolving and the fibrosing alveolitis model was especially taken into consideration in an attempt to identify fibrinolytic changes associated with the development of fibrosis. At the alveolitis stage, similarly increased BALF PA activities were measured in both the resolving and the fibrosing alveolitis models whereas only slight and no PA modifications were noted after administration of TiO2 and WC, respectively. Persistently (up to 120 d) increased BALF PA activity was selectively associated with the progression to fibrosis (DQ12), suggesting that PA is involved in the fibrotic process. ELISA measurements demonstrated that the changes in BALF PA activity were exclusively related to changes in urokinase (uPA), not tissue-type PA. A rapid and persisting (up to Day 30) upregulation of cell-associated PA activity occurred after DQ12, MnO2, and TiO2 treatment only. Cellular PA activity was however significantly higher in fibrogenic inflammatory cells recovered from DQ12 than from MnO2-treated mice suggesting that the intensity of cellular PA upregulation may represent an early indicator of the progression to fibrosis. The implication of urokinase in the pathogenesis of silica-induced fibrosis was demonstrated by the use of a uPA knockout mice. The acceleration of the fibrotic process in uPA-deficient compared with the wild type animals demonstrated the contribution of uPA to limit the fibrotic process.


Minerals , Pulmonary Fibrosis/chemically induced , Urokinase-Type Plasminogen Activator/physiology , Animals , Female , Lung/drug effects , Lung/pathology , Mice , Mice, Inbred Strains , Mice, Knockout/genetics , Minerals/pharmacology , Particle Size , Plasminogen Activators/metabolism , Pneumonia/chemically induced , Pneumonia/metabolism , Pneumonia/pathology , Silicon Dioxide/pharmacology , Urokinase-Type Plasminogen Activator/genetics
8.
J Toxicol Environ Health ; 51(2): 189-202, 1997 Jun 06.
Article En | MEDLINE | ID: mdl-9176558

We investigated the effect of intratracheally instilled coal fly ash (FA) and copper smelter dust (CU) on the lung integrity and on the ex vivo release of tumor necrosis factor alpha (TNF-alpha) by alveolar phagocytes. Groups of female NMRI mice received a single intratracheal administration of different particles normalized for the arsenic content (20 micrograms/kg body weight, i.e., 600 ng arsenic/mouse) and the particle load (100 mg/kg body weight, i.e., 3 mg/mouse). Mice received tungsten carbide (WC) alone (100 mg/kg), FA alone (100 mg/kg, i.e., 20 micrograms arsenic/kg), CU mixed with WC (CU, 13.6 mg/kg, i.e., 20 micrograms arsenic/kg; WC, 86.4 mg/kg) and Ca3(AsO4)2 mixed with WC (20 micrograms arsenic/kg; WC, 100 mg/kg). Animals were sacrificed at 1, 6, or 30 d posttreatment and analyzed by bronchoalveolar lavage for total protein (TP) content, inflammatory cell number and type, and TNF-alpha production. Additional mice were studied to evaluate particle retention by measuring total arsenic retention in the lung at appropriate times. Instillation of WC induced a mild and transient (d 1) inflammatory reaction characterized by an increase of TP and an influx of polymorphonuclear leukocytes in the alveolar compartment. Compared to WC, Ca3(AsO4)2 produced a significant increase of TP content in BALF. CU particles caused a severe but transient inflammatory reaction, while a persisting alveolitis (30 d) was observed after treatment with FA. Compared to control saline, a marked inhibition of TNF-alpha release was observed in response to LPS in all groups at d 1. Cytokine production was upregulated in WC- and Ca3(AsO4)1-treated animals after 6 and 30 d, respectively. However, a 90% inhibition of TNF-alpha production was still observed at d 30 after administration of CU and FA. Although arsenic was cleared from the lung tissue 6 d after Ca3(AsO4)2 administration, a significant fraction persisted (10-15% of the arsenic administered) in the lung of CU- and FA-treated mice at d 30. We hypothetize that suppression of TNF-alpha production is dependent upon the slow elimination of the particles and their metal content from the lung.


Carbon/toxicity , Coal/toxicity , Copper/toxicity , Phagocytes/drug effects , Pulmonary Alveoli/drug effects , Tumor Necrosis Factor-alpha/drug effects , Animals , Arsenic/analysis , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Coal Ash , Female , Intubation, Intratracheal , Lung/chemistry , Mice , Mice, Inbred Strains , Particle Size , Particulate Matter , Phagocytes/metabolism , Proteins/analysis , Pulmonary Alveoli/metabolism , Tumor Necrosis Factor-alpha/biosynthesis , Up-Regulation/drug effects
9.
Arch Toxicol ; 71(12): 725-9, 1997.
Article En | MEDLINE | ID: mdl-9388004

The objective of this study was to examine the influence of specific surface area on the biological activity of insoluble manganese dioxide (MnO2) particles. The biological responses to various MnO2 dusts with different specific surface area (0.16, 0.5, 17 and 62 m2/g) were compared in vitro and in vivo. A mouse peritoneal macrophage model was used to evaluate the in vitro cytotoxic potential of the particles via lactate dehydrogenase (LDH) release. In vivo, the lung inflammatory response was assessed by analysis of bronchoalveolar lavage after intratracheal instillation in mice (LDH activity, protein concentration and cellular recruitment). In both systems, the results show that the amplitude of the response is dependent on the total surface area which is in contact with the biological system, indicating that surface chemistry phenomena are involved in the biological reactivity. Freshly ground particles with a specific surface area of 5 m2/g were also examined in vitro. These particles exhibited an enhanced cytotoxic activity, which was almost equivalent to that of 62 m2/g particles, indicating that undefined reactive sites produced at the particle surface by mechanical cleavage may also contribute to the toxicity of insoluble particles. We conclude that, when conducting studies to elucidate the effect of particles on the lung, it is important for insoluble particles such as manganese dioxide to consider the administered dose in terms of surface area (e.g. m2/kg) rather than in gravimetric terms (e.g. mg/kg).


Lung/drug effects , Macrophages, Peritoneal/drug effects , Manganese Compounds , Manganese Poisoning , Oxides/toxicity , Pneumonia/chemically induced , Animals , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Cell Death/drug effects , Dust , L-Lactate Dehydrogenase/analysis , Leukocyte Count , Lung/pathology , Mice , Neutrophils , Particle Size , Proteins/analysis
10.
J Toxicol Environ Health ; 47(6): 509-22, 1996 Apr 19.
Article En | MEDLINE | ID: mdl-8614020

Enhancement of lung antioxidant capacity has been proposed in the therapy of acute lung injuries involving local accumulation of reactive oxygen species (ROS). We have studied in the female Sprague-Dawley rat the effect of intratracheal administration of catalase (CAT) on the acute lung response induced by different ROS generating systems. The lung response was assessed at several time intervals (60-360 min) by monitoring in bronchoalveolar fluid (BALF) the activity of lactate dehydrogenase and the levels of total protein, albumin, and glucose. While CAT (50,000 IU/rat) significantly reduced the biochemical changes induced by hydrogen peroxide produced by a glucose/glucose oxidase system, it markedly exacerbated the lesions induced by phorbol myristate acetate (PMA). Several observations indicate that a particular chemical species formed during the catalase inactivation process is responsible for this effect. Parallel to the development of the lung damage, we noted a rapid reduction of CAT activity (80%) in the BALF of animals treated with PMA and CAT. In vitro an inhibition of CAT activity was observed in the presence of a superoxide anion generating system, and this inhibition was prevented by superoxide dismutase (SOD). A dose of 10,000 IU superoxide dismutase did not prevent the development of the lung lesions induced by PMA plus CAT. Administered alone or in association with PMA, CAT inactivated by heat or 3-aminotriazole also caused severe lung damage. In conclusion, the present study indicates that exogenous catalase may not always protect against the inflammatory reaction resulting from an oxidative stress. In the presence of superoxide anions, catalase may aggravate the lesions, and this possibility should be kept in mind when considering an antioxidant therapy.


Catalase/toxicity , Lung/drug effects , Oxidative Stress , Reactive Oxygen Species/toxicity , Albumins/analysis , Analysis of Variance , Animals , Bronchoalveolar Lavage Fluid/chemistry , Carcinogens/toxicity , Catalase/administration & dosage , Disease Models, Animal , Drug Interactions , Drug Synergism , Female , Glucose/analysis , Hydrogen Peroxide/toxicity , In Vitro Techniques , L-Lactate Dehydrogenase/analysis , Lung/pathology , Oxidants/toxicity , Proteins/analysis , Rats , Rats, Sprague-Dawley , Tetradecanoylphorbol Acetate/toxicity , Trachea/drug effects
11.
Environ Res ; 69(2): 108-21, 1995 May.
Article En | MEDLINE | ID: mdl-8608770

Epidemiological and clinical studies suggest that inhalation of cobalt metal dust (Co) mixed with tungsten carbide particles (WC), but not of cobalt dust alone, may cause interstitial pulmonary lesions (hard metal disease). In previous experimental studies in the rat, we have demonstrated the greater acute pulmonary toxicity of a WC-Co mixture compared to Co or WC alone. The present study was undertaken to compare in the same animal model the delayed lung response after intratracheal administration of Co or WC-Co particles (cobalt particle 6.3 wt%). The responses were also compared with those obtained after treatment with arsenic trioxide and crystalline silica used a reference materials producing an acute toxic insult and a progressive fibrogenic response, respectively. Cellular (total and differential counts) and biochemical parameters (LDH, N-acetyl-beta-D-glucosaminidase, total protein, albumin, fibronectin, and hyaluronic acid) were measured in bronchoalveolar lavage fluid following single and repeated intratracheal instillations. The results indicate that the delayed lung response observed after WC-Co is different from that after cobalt metal alone. A single intratracheal dose of WC-Co (1, 5, or 10 mg/100 g body wt) induced an acute alveolitis which persisted for at least 1 month. Four months after a single instillation of WC-Co, no clear histological lung fibrosis could however be evidenced, indicating a reversibility of the lesions. The effects of cobalt (0.06, 0.3, or 0.6 mg/100 g body wt) or tungsten carbide alone (1, 5, 10 mg/ 100 g body wt) were very modest, if any. Following repeated intratracheal instillations (four administrations at 1-month interval), increased lung hydroxyproline content and histopathological evidence of interstitial fibrosis were observed after WC-Co (4 x 1 mg/100 g body wt), but not after administration of each component separately, i.e., Co (4 x 0.06 mg/100 g body wt) or WC (4 x 1 mg/100 g body wt). The mechanism of the fibrotic reaction induced by WC-Co seems different from the progressive inflammatory reaction induced by crystalline silica. We suggest that it might result from a scarring reaction elicited by repeated acute insults as observed after repeated administration of arsenic trioxide.


Cobalt/toxicity , Lung/drug effects , Tungsten Compounds/toxicity , Acetylglucosaminidase/metabolism , Albumins/metabolism , Animals , Arsenic Poisoning , Arsenic Trioxide , Arsenicals/administration & dosage , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Cobalt/administration & dosage , Disease Models, Animal , Female , Fibronectins/metabolism , Hyaluronic Acid/metabolism , L-Lactate Dehydrogenase/metabolism , Lung/chemistry , Lung/pathology , Oxides/administration & dosage , Oxides/toxicity , Powders , Proteins/metabolism , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/etiology , Rats , Rats, Sprague-Dawley , Silicon Dioxide/administration & dosage , Silicon Dioxide/toxicity , Staining and Labeling , Trachea/drug effects , Trachea/metabolism , Tungsten Compounds/administration & dosage
12.
Ann Cardiol Angeiol (Paris) ; 43(5): 293-9, 1994 May.
Article Fr | MEDLINE | ID: mdl-7521150

In this study, naftidrofuryl's action on vascular network regeneration is evaluated after cortical lesion produced by suction. The vascular reaction was analyzed in the region of the damaged cortex and the corresponding contralateral cortex. Comparison of results by variance analysis confirms that the effect of treatment is highly significant (p = 0.008). The results thus obtained show that post-lesion angiogenesis is facilitated and that capacities of post-lesion cerebral function regeneration could also be improved.


Brain Diseases/drug therapy , Brain/blood supply , Nafronyl/pharmacology , Neovascularization, Pathologic , Animals , Basement Membrane/pathology , Cell Division , Cerebral Cortex , Endothelium, Vascular/pathology , Female , Nafronyl/therapeutic use , Rats , Rats, Wistar , Time Factors
...